After raising over $30 million, and securing key channel access, Predictive Biosciences (developer of an LDT for bladder cancer) has closed operations because it couldn’t afford the level of validation required by a payer. From the article: “Predictive...
On-Q-ity, a Cancer Diagnostic Company: R.I.P. | LifeSciVC. Lots of lessons from this story, but two of the key ones are: 1. Clinical trials are costly and risky. The company’s first investments were in 4 clinical trials for their most promising biomarkers, all...
Interesting opinion piece rebutting an open letter from Peter Meldrum, CEO of Myriad, in advance of the Supreme Court’s decision on the patentability of BRCA1/BRCA2. Myriad Genetics CEO Claims He Owns Your Genes – Forbes. Patents support the public good...